Puma Biotech. (NYSE:PBYI) target price raised to $88.00, issued a report today by Stifel
- Updated: September 25, 2016
Puma Biotech. (NYSE:PBYI) had its price target upped to $88.00 by Stifel in a report released 09/21/2016. The bumped up target indicates a possible upside of 0.35% from the company's most recent stock price close.
On Tuesday March 29, 2016, RBC Capital Markets released a statement for Puma Biotech. (NYSE:PBYI) bumped down the target price from $103.00 to $36.00 that suggested an upside of 0.02%.
Boasting a price of $65.16, Puma Biotech. (NYSE:PBYI) traded 3.18% higher on the day. With the last stock price close up 71.03% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Puma Biotech. has recorded a 50-day average of $56.36 and a two hundred day average of $39.81. Volume of trade was up over the average, with 1,202,068 shares of PBYI changing hands over the typical 840,955
Recent Performance Chart
Puma Biotech. has with a one year low of $19.74 and a one year high of $94.93 and has a market capitalization of $0.
A total of 6 brokerages have issued a ratings update on Puma Biotech.. Two brokerages rating the company a strong buy, four brokerages rating the company a buy, two brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $95.50.
General Company Details For Puma Biotech. (NYSE:PBYI)
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.